PA-EXONE-CO.
9.11.2021 14:32:09 CET | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that global manufacturing innovation leader Siemens is the first of several customers to place an advance purchase for the InnoventPro 3L metal 3D printer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005404/en/
The InnoventPro is the world’s most advanced entry-level model for metal binder jetting — designed to take the easy-to-use features of the popular Innovent+ with patented Triple ACT advanced compaction technology and offer them with a bigger build area and the best speed and cutting-edge technology features of ExOne’s production-ready printers, such as the X1 25Pro® and X1 160Pro™.
The InnoventPro is slated to be on display for the first time in ExOne’s booth in Hall 12.0, Booth D69 at Formnext 2021 from Nov. 16-19 in Frankfurt, Germany. The machine is available for early-access machine customers in the first half of 2022, with broad availability to follow.
The InnoventPro features Siemens controls, which integrate with the printer drives, motors, sensors, as well as Siemens MindSphere IoT operating system, which powers ExOne’s Scout machine monitoring and analysis app.
Siemens will use the InnoventPro at its Charlotte Advanced Technology Collaboration Hub (CATCH) located in Charlotte, North Carolina to develop materials and processes before taking them to scale on the X1 160Pro.
“We’re very excited to feature the InnoventPro in our Technology Collaboration Hub, and we look forward to demonstrating how to integrate advanced additive manufacturing systems such as the InnoventPro into our end-to-end Digital Thread,” said Tim Bell, Head of Additive Manufacturing, Siemens Industry, Inc. The CATCH facility will leverage Siemens advanced hardware automation and software tools to continue the industrialization of additive manufacturing.
“ExOne is proud to continue offering Siemens technologies in our production-ready metal binder jetting systems, and we’re delighted that Siemens has purchased our new InnoventPro for its own manufacturing use,” said John Hartner, ExOne’s CEO. “Siemens technology continues to deliver important integration value to our production customers, and we’re confident our printer will deliver important manufacturing value to their operations as well.”
InnoventPro Feature Highlights
The affordable new InnoventPro is an all-new package built from the ground up that gives binder jetting customers the most advanced entry-level system on the market in a 3-liter build area of 125 x 220 x 100 mm. Features include:
- Triple ACT advanced compaction technology for precision dispensing, spreading, and compacting of ultra-fine MIM powders, delivering the industry-leading density, accuracy and repeatability that was proven on the Innovent+
- Now packaged with the same faster, smarter, recirculating printhead modules that come standard on ExOne production printers, enabling easy scalability to larger models
- The new printhead will be capable of speeds topping 700 cc/hour on the InnoventPro and printing a new class of patented NanoFuse™ binders embedded with nanoparticles to improve part quality and simplify sintering
- An innovative new comprehensive powder containment system, featuring the ergonomic X1 Powder Grip™ loading system, delivers ease-of-use and improved cleanliness
- Siemens MindSphere powers ExOne’s Scout machine monitoring and analysis app, part of ExOne’s strategy to surround its printers with a complete digital workflow. Scout is available today in the Apple App Store and on Google Play for use with ExOne production sand and metal 3D printers
The InnoventPro was designed by ExOne’s experienced binder jet engineering team based in Pittsburgh, Pennsylvania, and Gersthofen, Germany, with final manufacturing and assembly done in the United States.
Learn more about the InnoventPro at exone.com/innoventpro .
About ExOne
ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
About Siemens Digital Industries
Siemens Digital Industries (DI) is an innovation leader in automation and digitalization. Closely collaborating with partners and customers, DI drives the digital transformation in the process and discrete industries. With its Digital Enterprise portfolio, DI provides companies of all sizes with an end-to-end set of products, solutions and services to integrate and digitalize the entire value chain. Optimized for the specific needs of each industry, DI’s unique portfolio supports customers to achieve greater productivity and flexibility. DI is constantly adding innovations to its portfolio to integrate cutting-edge future technologies. Siemens Digital Industries has its global headquarters in Nuremberg, Germany, and has around 75,000 employees internationally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005404/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom